Customs Clearance Is Not a Delivery Date: Holds, Detentions, and Delay Planning

A shipment can be physically present in the United States without being legally available for delivery. An aircraft may have landed, a vessel may have berthed, or a carrier may show the freight as “arrived,” while the entry is still awaiting U.S. Customs and Border Protection (CBP) release, Food and Drug Administration (FDA) admissibility review, another government-agency decision, or the carrier’s own handling and recovery process.

For FDA-regulated medical devices, the customs broker submits entry data through CBP, which transmits relevant information to FDA. FDA may release the entry electronically, request documents, examine the shipment or labeling, collect a sample, or detain the goods if they appear noncompliant. Incomplete or inaccurate data can also cause an entry to be flagged for further review. Arrival is therefore only one milestone; delivery cannot safely be promised until the required government releases have been received and the carrier confirms that the freight can move.

Delivery Dates Carry Operational Consequences

This distinction matters most when dates carry operational consequences. A commercial launch should not depend on an inaugural import clearing on the day inventory is required. A customer installation, procedure, demonstration, or clinical-site shipment should not be scheduled on the assumption that a carrier’s estimated arrival date is a usable delivery date.

For temperature-sensitive goods, every additional day may consume validated shipping duration, require controlled storage, increase monitoring and handling costs, or create an excursion investigation before the product ever reaches its destination.

Delay Planning Begins Before Dispatch

Delay planning should begin before dispatch. Product descriptions, Harmonized Tariff Schedule classifications, FDA product codes, intended-use codes, manufacturer and establishment information, device listing details, consignee data, values, and supporting regulatory documents should be checked before the broker files the entry.

The importer should also know who will monitor the entry, who can answer a document request, where the shipment can be held under suitable conditions, and what authority exists to redirect, store, return, or replace it.

Build a Risk-Based Buffer

The appropriate buffer is risk-based rather than a fixed number of days. It should reflect the port, transport mode, product history, regulatory status, temperature limits, shipment value, and consequences of delay.

Launches and clinical programs should also retain contingency inventory in the United States where interruption would affect patient treatment, study continuity, contractual commitments, or customer confidence.

MDD Options can reduce this exposure through its hybrid distribution model by importing and holding U.S. inventory before the critical delivery date, including temperature-controlled or clinical-study stock. This separates customs and FDA uncertainty from the final customer or site shipment. Where clients retain their own import structure, MDD Options can also review entry readiness, supporting data, release responsibilities, storage contingencies, and inventory buffers before the shipment departs.